# Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19

> **NCT04716569** · PHASE2,PHASE3 · UNKNOWN · sponsor: **South Valley University** · enrollment: 150 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** intranasal ivermectin spray

## Key facts

- **NCT ID:** NCT04716569
- **Lead sponsor:** South Valley University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-20
- **Primary completion:** 2021-02-20
- **Final completion:** 2021-03-20
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2021-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04716569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04716569, "Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04716569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*